Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02993796 · ClinicalTrials.gov registry record

Krabbe Disease Global Patient Registry

A clinical trial of Krabbe Disease, sponsored by State University of New York at Buffalo.

Recruiting
Registry status
60
Enrollment target
1
Study location

NCT02993796 is a study of Krabbe Disease that is actively recruiting participants, run by State University of New York at Buffalo. The registered enrollment target is 60 participants, below the 404-participant average among 4 other Krabbe Disease trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02993796, a study of Krabbe Disease, is actively recruiting participants, sponsored by State University of New York at Buffalo.

RECRUITING
Registry status
60 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to develop a clinical database of individuals diagnosed with Krabbe disease in order to determine which symptoms herald the onset of clinical disease in the various phenotypes of Krabbe disease; to determine whether level of GALC enzyme activity, or a specific genetic mutation predict the clinical course; and to determine which neurodiagnostic tests predict onset and/or severity of the disease.

Conditions Studied

Study Locations (1)

New York

  • State University of New York at Buffalo - Buffalo

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2014-09
Est. Completion 2026-09

What the Registry Record Tells You About NCT02993796

The ClinicalTrials.gov registry entry for NCT02993796 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 404-participant average among 4 other Krabbe Disease trials with a reported enrollment target (85% lower). The listed sponsor is State University of New York at Buffalo, which has 243 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Krabbe Disease appearing as the primary indexed condition, and to 0 interventions.

NCT02993796 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT02993796 about?

NCT02993796 is a clinical study titled "Krabbe Disease Global Patient Registry". The purpose of this study is to develop a clinical database of individuals diagnosed with Krabbe disease in order to determine which symptoms herald the onset of clinical disease in the various phenotypes of Krabbe disease; to determine whether level of GALC enzyme activity, or a specific genetic mu...

What is the current status of trial NCT02993796?

This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2014-09. Estimated completion is 2026-09.

What conditions does trial NCT02993796 study?

This clinical trial studies the following conditions: Krabbe Disease.

Who is sponsoring clinical trial NCT02993796?

This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02993796 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Krabbe Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.